Advertisement
Advertisement
U.S. markets close in 4 hours 28 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Bellicum Pharmaceuticals, Inc. (BLCM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.7200-0.0100 (-0.58%)
As of 11:14AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close1.7300
Open1.7600
Bid1.7000 x 1300
Ask1.7200 x 1100
Day's Range1.6800 - 1.7900
52 Week Range1.6600 - 8.1500
Volume22,884
Avg. Volume136,906
Market Cap14.444M
Beta (5Y Monthly)1.52
PE Ratio (TTM)2.51
EPS (TTM)0.6860
Earnings DateNov 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLCM

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bellicum Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/01/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update

    - Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief Development Officer effective December 1, 2021 - HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2021 and provided an opera

  • GlobeNewswire

    Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

    HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference (Virtual). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 13, 2021 and will remain accessible for 90 days in the Events and Presenta

  • Benzinga

    38 Stocks Moving In Wednesday's Mid-Day Session

    Gainers Focus Universal Inc. (NASDAQ: FCUV) shares jumped 108.2% to $10.62. The stock started trading on Nasdaq Capital Market yesterday. Sequential Brands Group, Inc. (NASDAQ: SQBG) gained 36.4% to $7.00. Sequential Brands Group recently commenced voluntary Chapter 11 proceedings. Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) surged 30% to $3.89 after the company, and MD Anderson, announced an additional license agreement for use of CaspaCIDe safety switch. ABVC BioPharma, Inc. (NASDAQ: ABVC) s

Advertisement
Advertisement